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Abstract
Background: Biomarkers to differentiate between active tuberculosis (TB) and latent TB infection (LTBI) and to monitor
treatment responses are requested to complement TB diagnostics and control, particularly in patients with multi-drug
resistant TB. We have studied soluble markers of the Toll-like-receptor 4 (TLR-4) pathway in various stages of TB disease and
during anti-TB treatment.
Methods: Plasma samples from patients with culture confirmed drug-sensitive TB (n = 19) were collected before and after 2,
8 and 24 weeks of efficient anti-TB treatment and in a LTBI group (n = 6). Soluble (s) CD14 and myeloid differentiation-2 (MD-
2) were analyzed by the Enzyme-linked immunosorbent assay (ELISA). Lipopolysaccharide (LPS) was analyzed by the Limulus
Amebocyte Lysate colorimetric assay. Nonparametric statistics were applied.
Results: Plasma levels of sCD14 (p,0.001), MD-2 (p = 0.036) and LPS (p = 0.069) were elevated at baseline in patients with
untreated active TB compared to the LTBI group. MD-2 concentrations decreased after 2 weeks of treatment (p = 0.011),
while LPS levels decreased after 8 weeks (p = 0.005). In contrast, sCD14 levels increased after 2 weeks (p = 0.047) with a
subsequent modest decrease throughout the treatment period. There was no significant difference in concentrations of any
of these markers between patients with pulmonary and extrapulmonary TB or between patients with or without symptoms.
Conclusion: Our data suggest that plasma levels of LPS, MD-2 and sCD14 can discriminate between active TB and LTBI. A
decline in LPS and MD-2 concentrations was associated with response to anti-TB treatment. The clinical potential of these
soluble TLR-4 pathway proteins needs to be further explored.
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Introduction
Tuberculosis (TB) is a global challenge and there were an
estimated 8.7 million incident cases in 2011, 13% were co-infected
with human immunodeficiency virus (HIV) and 20% of previously
treated cases had multi-drug resistant (MDR)-TB [1]. Both TB
culture, which is the diagnostic gold standard, and the Xpert MTB/
RIF assay often fail in cases of extrapulmonary TB, in HIV-
infection and in children [2] and TB diagnosis is often made on
clinical criteria. Thus, leading stakeholders have called for
intensified basic scientific research to explore TB immunopatho-
genesis and screen for diagnostic and prognostic biomarker
candidates that could complement diagnosis [3–5]. Predictors of
treatment efficacy are particularly relevant in MDR-TB with less
efficient therapeutic regimens of longer duration.
A number of TB antigens have been tested as potential
biomarkers [6,7]. Available serology tests are unreliable even
though they are in extensive use in some TB high-endemic
countries [8,9]. Several meta-analyses show that the cellular
interferon- gamma- release- assays (IGRAs) are at least as sensitive
and more specific than the tuberculin skin test (TST) [10–13]. Still,
they do not discriminate between latent TB infection (LTBI) and
active TB and cannot monitor therapy.
Mycobacterium tuberculosis (Mtb) possesses a unique cell envelope
with an outer lipid layer of mycolic acids and intercalated
additional complex lipids, which have been the targets for
immunogenic, diagnostic and drug research [14]. Mtb synthesize
two unique families of cytoplasmic polymethylated polysaccha-
rides, the methylglucose lipopolysaccharides (MGLPs) and the
methylmannose polysaccharides (MMPs) [15–17]. Cell wall-
associated lipoglycans such as lipoarabinomannan (LAM) inhibit
the expression of pro-inflammatory cytokines by activated
macrophages and has been identified as a major virulence factor
of Mtb [18]. Whereas the point-of-care LAM urine antigen test
could aid in the diagnosis of advanced HIV-associated TB [19],
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the overall low sensitivity in HIV negative TB patients may still
limit this test’s utility [20].
Toll-like receptors (TLR), essential membrane receptors that
recognize pathogen-associated molecules, interact with specific
Mtb structures triggering signaling pathways [21]. Various types of
LPS induce synthesis of proinflammatory cytokines through
binding to the TLR-4/myeloid differentiation-2 (MD-2) complex
[22,23]. Several soluble proteins regulate the signaling of LPS
through the TLR-4 pathway. CD14, a glycoprotein expressed on
the surface of macrophages, monocytes and phagocytes seems to
be essential in the host response against microbial infection
[24,25]. Soluble (s) CD14 serves as a receptor for the complex of
LPS and LPS binding protein (LBP) and plays a central role by
transferring LPS to MD-2, thus activating immune responses to
bacterial endotoxins [22,26]. Elevated levels of sCD14 are
associated with various systemic inflammatory diseases including
TB [27], and increased levels of MD-2 have been detected in
plasma from patients with severe sepsis as well as in HIV infection
[28,29]. It has been shown that during anti-TB treatment the
levels of sCD14 slowly decline [27] and the levels of LBP are lower
in treated compared to untreated TB patients [30]. To our
knowledge, however, there are no longitudinal studies of
circulating levels of MD-2, sCD14 and LPS in TB patients or of
the possible effects of anti-TB treatment upon these potential
biomarkers. Our pilot study indicates that plasma levels of LPS
and MD-2 can discriminate between various stages of TB disease
and possibly predict responses to therapy.
Materials and Methods
Study Participants
Nineteen patients with active culture-confirmed TB, ten with
pulmonary and nine with extrapulmonary TB, were recruited
from the Department of Infectious Diseases, Oslo University
Hospital, Norway. Demographical and clinical data were as
described in Table 1. Two patients were native Norwegians (age
81 and 92) and the remaining were immigrants, predominately
from Africa (n = 9) and Asia (n = 6). Patients were classified as
symptomatic when they presented with two or more of the
following symptoms: fever (temperature.38uC), weight loss,
wasting, cough and night-sweat. Nine had symptomatic TB while
the others were diagnosed in routine screening or investigations for
other medical conditions. The erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), thoracic X ray, acid-fast staining
and culture of sputum results were registered upon inclusion. All
Mtb strains were drug-sensitive. Patients were treated with a
standard combination of four drugs (isoniazid, rifampicin,
ethambutol and pyrazinamide) for 2 months, followed by isoniazid
and rifampicin for 4 months. Sputum samples were assessed after 2
and 6 months of treatment and patients were also evaluated after
one year according to clinical practice. All patients responded to
treatment, pulmonary TB patients with sputum conversion and
culture clearing whereas extrapulmonary TB patients demonstrat-
ed clinical improvement and normalization of inflammation
parameters (CRP, ESR). No relapse was observed during the
year of follow-up. Six subjects with LTBI were recruited from
Haukeland University Hospital, Bergen. Two were native
Norwegians and four immigrants. All LTBI tested positive with
the QuantiFERON-TBH test (Cellestis/Qiagen). Thoracic X-ray,
sputum smears and clinical examinations were performed and
there were no signs of active TB in any of the persons. Both active
TB and LTBI patients were HIV negative.
Blood samples were obtained by venipuncture prior to start of
treatment (baseline), after 2, 8 and 24 weeks in the active TB
group and at the time of diagnosis in the LTBI group. Plasma
samples were separated and snap-frozen within 30 minutes and
stored at minus 80uC until analysis.
The study was approved by the respective Regional Boards for
Medical and Health Research Ethics in Norway (in Health region
South-East and West). Written informed consent was obtained
from all participants.
Lipopolysaccharide Assay
We observed that the Limulus Amebocyte Lysate colorimetric
assay (LAL) (Lonza, Walkersville, MD, USA) could detect TB-
specific LAM from the General LAM Enzyme-linked immuno-
sorbent assay (ELISA) kit (Wuhan Eiaab Science, Whuan, China)
in a dose dependent manner, indicating that the LAL assay could
detect mycobacterial LPS (Fig. 1). We then analyzed LAM in
plasma samples from the active TB group in 8- and 24-fould
dilutions according to the manufacturer’s instructions. However,
Table 1. Demographic and clinical characteristics of study
participants.
Active TB Latent TB
N = 19 N = 6
Median age (years)1 32 (26–41) 40 (26–54)
Sex Female 9 4
Male 10 2
Country of origin Africa 9 2
Asia 6 2
Europe 42 23
Localisation of disease Pulmonary 10
Extrapulmonary 9
Symptomatic TB4 9
1Interquartile range in brackets.
2Including two native Norwegians.
3All native Norwegians.
4$2 of the following symptoms: fever (temperature.38uC), weight loss,
wasting, cough and night-sweat.
doi:10.1371/journal.pone.0069896.t001
Figure 1. Lipoarabinomannan (LAM) detected by the Lipopo-
lysaccaride (LPS) assay. Relation between Lipoarabinomannan
(LAM) standard concentrations from the Enzyme-linked immunosorbent
assay (ELISA) kit and Lipopolysaccaride (LPS) concentrations analysed
by the Limulus Amebocyte Lysate colorimetric assay (LAL).
doi:10.1371/journal.pone.0069896.g001
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about 40% of the tested samples were below twice the background
optic density value and thereby not quantifiable (data not shown).
LPS concentrations in plasma were then analyzed in duplicates
by the LAL colorimetric assay according to the manufacturer’s
instructions with the following modifications: plasma samples were
diluted 10-fold to avoid interference with background color and
preheated to 68uC for 12 minutes prior to analyses to dissolve
immune complexes as previously described [29]. Test samples
were mixed with the LAL supplied in the test kit and incubated at
37uC for 10 minutes. A substrate solution was then mixed with the
LAL sample and incubated at 37uC for an additional 6 minutes
and the reaction was stopped. A conversion to yellow developed if
LPS was present. The absorbance of the sample was determined
Figure 2. Lipopolysaccharide levels at various stages of TB infection and during therapy. Lipopolysaccharide (LPS) concentrations (pg/ml)
in plasma from A) patients with LTBI (n = 6) and active TB (n = 19) at baseline and after 8 and 24 weeks of anti-TB therapy and B) active TB (n = 10) at
baseline and after 2 weeks of anti-TB therapy. Horizontal lines represent the median values. Significant p values (,.05) between groups and time-
points are indicated.
doi:10.1371/journal.pone.0069896.g002
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by spectrophotometer and concentration calculated from a
standard curve.
Myeloid Differentiation-2 ELISA
MD-2 was analyzed by an in-house ELISA as previously
described [31]. Briefly, MD-2 was captured on immunoplates
coated with a TLR-4-Fc fusion protein and detected with
digoxygenin labeled MD-2 mAb 5D7 or digoxigenin labeled
IIC1 and anti-digoxygenin-HRP (Roche). The MD-2 standard
was purchased from R&D Systems.
Soluble CD14 ELISA
sCD14 was analyzed by a sandwich ELISA coated with CD14-
specific monoclonal antibodies according to the manufacturer’s
instructions (R&D, Minneapolis, MN, USA). Samples were diluted
300-fold and incubated in duplicates for three hours at room
temperature. After a total of four washing steps, the wells were
incubated with sCD14 conjugate solution for one hour. The cells
were washed, substrate solution added, incubated for 30 minutes
and stopped. A conversion to blue developed if sCD14 was
present, the absorbance of the sample was determined by
spectrophotometer and concentrations were calculated from a
standard curve.
Inflammation Markers
CRP was estimated by Immuno Turbidometric assay (Cobas
8000, Roche Diagnostics, USA) and ESR according to Westergren
Method (StaRRsed Compact Automatic Analyzer, RRmechatro-
nic, Hoom, the Netherlands).
Statistical Analysis
Statistical analyses were performed by Statistica v 7.0 (Statsoft,
Tulsa, OK, USA). Nonparametrical statistical methods were
applied for group-wise comparison. Mann-Whitney U test and
two-tailed Wilcoxon matched pairs test for dependent variables.
Correlation analyses were performed using the Spearman method.
A significance level of 0.05 was used. All values are presented as
median and interquartile range (IQR).
Results
Elevated Plasma Lipopolysaccharide Levels Decline
during TB Treatment
Plasma levels of LPS at baseline were higher, although not
significant, in the active TB group compared to the LTBI group
(60 pg/mL [44–77] vs. 39 pg/mL [31–63], p = 0.069) (Fig. 2A). In
the active TB group LPS levels decreased significantly during
treatment (49 pg/mL [43–57], p = 0.005 at week 8). The decline
in LPS level was maintained at week 24 (48 pg/mL [37–52],
p = 0.018). No significant decline was observed from baseline to
week 2, measured in ten of the patients (Fig. 2B). LPS
concentrations did not differ significantly between patients with
pulmonary and extrapulmonary TB (60 pg/mL [44–69] vs.
59 pg/mL [48–77]).
Elevated Plasma Myeloid Differentiation-2 Levels Rapidly
Decline during TB Treatment
Plasma levels of MD-2 at baseline were higher in the active TB
group compared to the LTBI group (3200 ng/ml [2100–4320]) vs.
1815 ng/ml [1530–2320], p = 0.036) (Fig. 3). In active TB patients
there was a rapid decline in the level of MD-2 compared to
baseline, significant already after 2 weeks of treatment (2300 ng/
ml [2100–4300], p= 0.011), and still significant at week 8
(2125 ng/ml [2000–3450], p= 0.028) and week 24 (1895 ng/ml
[1560–2200], (p = 0.001). MD-2 concentrations did not differ
significantly between patients with pulmonary and extrapulmo-
nary TB (2655 ng/mL [1820–5420] vs. 3200 ng/ml [2300–
3260]).
Figure 3. Myeloid differentiation-2 levels at various stages of TB infection and during therapy. Myeloid differentiation-2 (MD-2)
concentrations (ng/ml) in plasma from patients with LTBI (n = 6) and active TB (n = 19) at baseline and after 2, 8 and 24 weeks of anti-TB therapy.
Horizontal lines represent the median values. Significant p values (,.05) between groups and time-points are indicated.
doi:10.1371/journal.pone.0069896.g003
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Elevated Plasma Levels of sCD14 during TB Treatment
Plasma levels of sCD14 at baseline were higher in the active TB
group compared to the LTBI group (2320 ng/ml [1990–3720] vs.
1335 ng/ml [1190–1450], p,0.001) (Fig. 4A). After 2 weeks of
therapy there was a significant increase in sCD14 in the active TB
group (2820 ng/ml [2190–3650], p= 0.047) (Fig. 4B). A slightly
decrease in median sCD14 was observed after 24 weeks of therapy
(2220 ng/ml [1920–2800]), although not significant (p = 0.064)
(Fig. 4A). sCD14 levels did not differ between patients with
pulmonary and extrapulmonary TB (2450 ng/ml [2200–3720] vs.
2240 ng/mL [1640–2475]).
Correlations between sCD14, LPS, MD-2 and
Inflammation Markers
Nine active TB patients were categorized as symptomatic at
baseline. The inflammation markers CRP and ESR were
significantly higher in the symptomatic compared to the asymp-
tomatic TB group (77 mg/L [36–95] vs. 24 mg/L [3–18],
Figure 4. sCD14 levels at various stages of TB infection and during therapy. Soluble CD14 concentrations (ng/ml) in plasma from A)
patients with LTBI (n = 6) and active TB (n = 19) at baseline and after 8 and 24 weeks of anti-TB therapy and B) active TB (n = 10) at baseline and after 2
weeks of anti-TB therapy. Horizontal lines represent the median values. Significant p values (,.05) between groups and time-points are indicated.
doi:10.1371/journal.pone.0069896.g004
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p= 0.017 and 67 mm [50–80] vs. 43 mm [27–56], p = 0.028,
respectively), but CRP and ESR could not discriminate between
pulmonary and extrapulmonary TB. At baseline there were
significant correlations between CRP and sCD14 (r = 0.492,
p = 0.032) while the correlation between ESR and sCD14 was
modest (r = 0.438, p = 0.060) (Fig. 5). LPS or MD-2 did not
correlate to either CRP or ESR. There were no significant
differences in levels of LPS, sCD14 and MD-2 between patients
with high or low symptom score or between patients with
pulmonary and extrapulmonary TB (data not shown).
Discussion
Mycobacterial cell wall components are immunogenic and thus
potential biomarkers for TB [14]. Proteins involved in the
regulation of innate immunity through the TLR-4 pathway could
also serve as surrogates for TB disease [21]. We have analyzed
plasma concentrations of LPS, sCD14 and MD-2 in patients with
various clinical manifestations and stages of TB infection and
during anti-TB treatment. We have shown that plasma levels of
MD-2, sCD14 and possibly LPS are higher in patients with active
TB than in LTBI. Most important, we found that the decline in
LPS and MD-2 concentrations was associated with response to
anti-TB treatment. sCD14 transfers LPS to MD-2, thus activating
immune responses to bacterial endotoxins [22,26]. Immunoregu-
latory cytokines such as IL-10 downregulate protective immune
responses in chronic active TB infection [32] and seems to be a
driving force for increased release of MD-2 and CD14 during
systemic inflammation [31]. Thus, the decline in these markers, for
MD-2 measured already after 2 weeks, could reflect an early
down-regulation of immune activation during effective anti-TB
therapy. The decline in LPS levels supports an Indian study where
they isolated an immunodominant LPS antigen from Mtb H37Rv
and compared LPS with three commercially available Mtb-specific
antigens for detection of TB [33]. They found that LPS sensitivity
was 84% and specificity 97%, suggesting that the LPS antigen
could be used in sero-diagnosis of TB. Further, a recent study on
circulating biomarkers demonstrated that LPS was elevated in
plasma from children with pulmonary TB, arguing that LPS might
serve as a marker of innate immune activation [34]. Previous
studies have also shown that proteins involved in the innate
immune activation are elevated in other infectious diseases as
parasitic infections [35], HIV infection [36] and hepatitis [37].
Increased circulating LPS could result from chronic immune
activation caused by microbial translocation as has been demon-
strated in HIV infection [36,38]. We think, however, that in our
patients this is less likely as none had gastrointestinal or
disseminated TB. In contrast to that found for MD-2 we did not
record any changes in LPS levels after 2 weeks of treatment. Wood
et al showed a decline in urine LAM concentrations in South-
African patients treated for active TB between 2 and 8 weeks of
treatment [39], and given the apparently higher sensitivity of our
LAL-assay, further investigations of the time kinetics of LPS
during anti-TB should be performed.
We found higher levels of sCD14 in plasma from patients with
active TB compared to those with LTBI, as shown in previous
studies [27,30]. We observed a very modest and not statistical
significant decline of sCD14 throughout the 24 week observation
period. Whereas Juffermans et al found normalization of sCD14
levels in TB patients that had completed curative treatment [30],
Lawn et al showed that the levels of sCD14 declined slowly and
were still significantly elevated after 3 months of treatment, in
support of our data [27].
Still, we detected increased plasma levels of sCD14 at week 2 of
TB treatment in a smaller group of patients where plasma samples
were available. Lawn et al also observed a similar transient
increase during the first month of treatment, followed by a slow
decline in serum sCD14 concentrations [27]. They argue that the
initial rise in sCD14 levels might represent the host response to the
increase of mycobacterial antigen load due to therapy correspond-
ingly to what has been previously shown for tumour necrosis factor
alpha (TNF-a) [40].Our data supports this conclusion, although
the mechanisms need to be further documented by in vitro studies.
In our study sCD14 levels correlated to some extent to CRP
levels, suggesting that both these markers reflect the level of
inflammation [41]. In contrast, we did not find correlations
between inflammation markers and LPS or MD-2 plasma levels,
respectively. It has been shown that cell wall-associated lipids
inhibit LPS-induced TNF-a release by a sCD14-dependent
pathway, while IL-12 p40 inhibition is sCD14-independent [42].
Such mechanisms could explain the diverse associations detected
for the various markers.
In our study the parameters did not discriminate between either
disease localization or symptom score. One would assume
significantly lower plasma levels of sCD14 in extrapulmonary
TB compared to pulmonary TB due to the expected various levels
Figure 5. Correlations between sCD14 and inflammation
markers. Correlations between inflammation markers in the active
TB group (n = 19) between A) CRP and sCD14 (r = 0.492, p = 0.032), B)
ESR and sCD14 (r = 0.438, p = 0.060).
doi:10.1371/journal.pone.0069896.g005
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of bacillary load [30]. However, all extrapulmonary TB patients in
our study had positive TB cultures and neither CRP nor ESR
could discriminate between pulmonary and extrapulmonary TB.
In fact, several of the extrapulmonary cases had much higher
levels of inflammation markers than that found in many of the
patients with pulmonary TB. This, as well as the relatively low
numbers of patients in each group, could explain why we did not
find any significant difference for sCD14, LPS and MD-2 between
these two patient groups. Of note, the rapid decline in MD-2 in
response to therapy was also seen in those patients with none or
few symptoms where clinical improvement would be of less use as
parameter of therapy efficacy. Thus, MD-2 could potentially serve
as a complimentary biomarker when evaluating the initial
response to therapy in patients with few symptoms.
The limitation of this study is the small sample size, which
increases the risk of type II statistical errors. However, since type I
errors are less likely, both our findings that MD-2 and sCD14 can
discriminate between latent and active TB and that MD-2 and
LPS are associated with treatment responses are probably valid.
Further, the LAL assay might be less specific in patients with
concurrent HIV infection and increased levels of LPS due to
microbial translocation [43].
In conclusion, based on our data and other reports, a multi-
parameter approach including biomarkers must be considered to
aid in TB diagnosis and monitor efficacy of TB treatment [5,44].
The clinical importance of these TLR-4 regulatory proteins is yet
to be determined. Still, our explorative novel data indicate that
these soluble markers, in particular MD-2, need to be further
studied in larger cohorts of TB patients.
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